Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress
暂无分享,去创建一个
Monika Aggarwal | Robert M Brosh | R. Shoemaker | R. Brosh | J. Sommers | Robert H Shoemaker | M. Aggarwal | Joshua A Sommers
[1] G. Dianov,et al. WRN helicase and FEN-1 form a complex upon replication arrest and together process branchmigrating DNA structures associated with the replication fork. , 2003, Molecular biology of the cell.
[2] K. Shin‐ya,et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia , 2006, Oncogene.
[3] G. Martin. Genetic syndromes in man with potential relevance to the pathobiology of aging. , 1978, Birth defects original article series.
[4] U. Hübscher. DNA replication fork proteins. , 2009, Methods in molecular biology.
[5] R. Brosh,et al. Biochemical Characterization of the DNA Substrate Specificity of Werner Syndrome Helicase* , 2002, The Journal of Biological Chemistry.
[6] K. Doherty,et al. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability. , 2006, The Biochemical journal.
[7] David J. Chen,et al. WRN exonuclease structure and molecular mechanism imply an editing role in DNA end processing , 2006, Nature Structural &Molecular Biology.
[8] K. Shin‐ya,et al. G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3′ telomeric overhang in cancer cells , 2006, Oncogene.
[9] S. Cantor,et al. Analysis of the DNA Substrate Specificity of the Human BACH1 Helicase Associated with Breast Cancer* , 2005, Journal of Biological Chemistry.
[10] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[11] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[12] Ian D. Hickson,et al. RecQ helicases: multifunctional genome caretakers , 2009, Nature Reviews Cancer.
[13] Thomas Helleday,et al. DNA repair pathways as targets for cancer therapy , 2008, Nature Reviews Cancer.
[14] Monika Aggarwal,et al. Hitting the bull's eye: Novel directed cancer therapy through helicase‐targeted synthetic lethality , 2009, Journal of cellular biochemistry.
[15] I. Hickson. RecQ helicases: caretakers of the genome , 2003, Nature Reviews Cancer.
[16] A. Vindigni,et al. Biochemical Analysis of the DNA Unwinding and Strand Annealing Activities Catalyzed by Human RECQ1*[boxs] , 2005, Journal of Biological Chemistry.
[17] R. Verdun,et al. Defective Telomere Lagging Strand Synthesis in Cells Lacking WRN Helicase Activity , 2004, Science.
[18] K. Shin‐ya,et al. The G-Quadruplex Ligand Telomestatin Impairs Binding of Topoisomerase IIIα to G-Quadruplex-Forming Oligonucleotides and Uncaps Telomeres in ALT Cells , 2009, PloS one.
[19] T. Helleday. Amplifying tumour-specific replication lesions by DNA repair inhibitors - a new era in targeted cancer therapy. , 2008, European journal of cancer.
[20] V. Bohr,et al. Human premature aging, DNA repair and RecQ helicases , 2007, Nucleic acids research.
[21] K. Shin‐ya,et al. The G-quadruplex ligand telomestatin inhibits POT1 binding to telomeric sequences in vitro and induces GFP-POT1 dissociation from telomeres in human cells. , 2006, Cancer research.
[22] B. Kennedy,et al. Werner and Hutchinson–Gilford progeria syndromes: mechanistic basis of human progeroid diseases , 2007, Nature Reviews Molecular Cell Biology.
[23] Ian D. Hickson,et al. The Bloom's and Werner's syndrome proteins are DNA structure-specific helicases , 2001, Nucleic Acids Res..
[24] L. Loeb,et al. Human Werner Syndrome DNA Helicase Unwinds Tetrahelical Structures of the Fragile X Syndrome Repeat Sequence d(CGG) n * , 1999, The Journal of Biological Chemistry.
[25] A. Folch,et al. The RecQ helicase WRN is required for normal replication fork progression after DNA damage or replication fork arrest , 2008, Cell cycle.
[26] R. Brosh,et al. Helicases as prospective targets for anti-cancer therapy. , 2008, Anti-cancer agents in medicinal chemistry.
[27] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.